Prot #PCYC-1117-CA: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

Project: Research project

Project Details

StatusFinished
Effective start/end date4/22/136/20/15

Funding

  • Quintiles, Inc. (Prot #PCYC-1117-CA)
  • Pharmacyclics, Inc. (Prot #PCYC-1117-CA)